Versorgung einer Zweitschwangerschaft nach fetaler/neonataler Alloimmunthrombozytopenie (FNAIT) von HPA-1a-heterozygotem Vater

Zusammenfassung

Die fetale/neonatale Alloimmunthrombozytopenie (FNAIT) ist das thrombozytäre Äquivalent zum Morbus haemolyticus neonatorum, kann jedoch im Gegensatz zu diesem bereits in der ersten Schwangerschaft auftreten. Die Ursache sind plazentagängige mütterliche Alloantikörper gegen vom Vater vererbte humane Plättchenantigene (HPA). Am häufigsten sind Anti-HPA-1a-Antikörper, die klinisch eher mit schwerwiegenden Verläufen einschließlich Hirnblutungen assoziiert sind. Das Wiederholungsrisiko für Folgeschwangerschaften beträgt meist 100 %, bei HPA-1a-heterozygotem Vater jedoch nur 50 %. Anhand einer Kasuistik wird über neuere diagnostische und therapeutische Optionen unter besonderer Berücksichtigung der fetalen HPA-Typisierung aus peripherem mütterlichem Blut berichtet.

Abstract

Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is the platelet counterpart to the haemolytic disease of the newborn, but may already occur during the first pregnancy. It is caused by maternal allo-antibodies against human platelet antigens (HPA) that the fetus inherited from the father. The most common specificity is anti-HPA-1a, which is associated with rather severe clinical courses including intracranial haemorrhages. Unfortunately, the recurrence risk for further pregnancies is quite often 100 %. However, it is only 50 % if the father is heterozygous for HPA-1a. New options in diagnosis and therapy are reported based on a recent case with focus on the fetal HPA-1 genotyping from maternal peripheral blood.

Schlüsselwörter

fetale/neonatale Alloimmunthrombozytopenie (FNAIT) - humane Plättchenantigene (HPA) - nicht invasive fetale HPA-Typisierung - HPA-1a-Heterozygotie - intravenöse Immunglobuline (IVIG)

Key words

fetal and neonatal alloimmune thrombozytopenia (FNAIT) - human platelet antigens (HPA) - fetal HPA-1 genotyping heterozygosity for HPA-1a - intravenous immunoglobulins (IVIG)

• Literatur

• 1 Porcelijn L, Van den Akker ES, Oepkes D. Fetal thrombocytopenia. Semin Fetal Neonatal Med 2008; 13: 223-230
• 2 Arnold DM, Smith JW, Kelton JG. Diagnosis and management of neonatal alloimmune thrombocytopenia. Transfus Med Rev 2008; 22: 255-267
• 3 Roberts I, Murray NA. Neonatal thrombocytopenia. Semin Fetal Neonatal Med 2008; 13: 256-264
• 4 Bakchoul T, Kubiak S, Krautwurst A et al. Low-avidity anti-HPA-1a alloantibodies are capable of antigen-positive platelet destruction in the NOD/SCID mouse model of alloimmune thrombocytopenia. Transfusion 2011; 51: 2455-2461
• 5 Kiefel V, Bassler D, Kroll H et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006; 107: 3761-3763
• 6 Kumpel BM. Would it be possible to prevent HPA-1a alloimmunization to reduce the incidence of fetal and neonatal alloimmune thrombocytopenia?. Transfusion 2012; 52: 1393-1397
• 7 Turner ML, Bessos H, Fagge T et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 2005; 45: 1945-1956
• 8 Tiller H, Killie MK, Chen P. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion 2012; 52: 1446-1457
• 9 Kaplan C, Daffos F, Forestier F et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood 1988; 72: 340-343
• 10 Bussel JB, Berkowitz RL, McFarland JG, Lynch L et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988; 319: 1374-1378
• 11 Kamphuis MM, Oepkes D. Fetal and neonatal alloimmune thrombocytopenia: prenatal interventions. Prenat Diagn 2011; 31: 712-719
• 12 Paidas MJ, Berkowitz RL, Lynch L et al. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995; 172: 475-479
• 13 Bussel JB, Berkowitz RL, Hung C et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol 2010; 203: 135
• 14 Bertrand G, Drame M, Martageix C et al. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood 2011; 117: 3209-3213
• 15 Scheffer PG, Ait Soussan A, Verhagen OJ et al. Noninvasive fetal genotyping of human platelet antigen-1a. BJOG 2011; 118: 1392-1395
• 16 Le Toriellec E, Chenet C, Kaplan C. Safe fetal platelet genotyping: new developments. Transfusion 2012;